1Packard RR, Libby P. Inflammation in atherosclerosis:from vascular biology to biomarker discovery and risk prediction [J]. Clin Chem, 2008 ; 54 ( 1 ) :24-38.
2Rehli M, Niller HH, Ammon C, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation [ J]. J Biol Chem,2003 ;278 (45) :44058-67.
3Nishikawa KC ,Millis AJ. GP38k (CHI3L1) is a novel adhesion and migration factor for vascular cells[J].Exp Cell Res,2003 ;287 ( 1 ) :79-87.
4Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with re- lation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis [ J]. Inflamm Res ,2006 ;55 (6) :221-7.
5Baeten D, Boots AM, Steenbakkers PG, et al. Human cartilage gp-39 + , CD16 + monoeytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis [J]. Arthritis Rheum, 2000 ; 43 (6) :1233-43.
6Ostergaard C, Johansen JS, Benfield T,et al. YKL-d0 is elevated in cerebrospinal fluid from patients with purulent meningitis[J]. Clin Diagn Lab Immunol, 2002 ;9 ( 3 ) :598 -604.
7Johansen JS, Krabbe KS, Moiler K, et al. Circulating YKL-40 levels during human endotoxaemia [J].Clin Exp Immunol,2005 ; 140 ( 2 ) : 343-8.
8Fach EM, Garulacan LA, Gao J, et al. In vitro biomarker discovery for atherosclerosis by proteomics [J].Mol Cell Proteomics, 2004 ; 3 ( 12 ) : 1200-10.
9Schrijvers DM, de Meyer GR, Herman AG, et al. Phagocytosis in athero- sclerosis:moieeular mechanisms and implications for plaque progression and stability[J].Cardiovasc Res,2007 ;73 (3) :470-80.
10Nojgaard C, Host NB, Christensen IJ, et al. Serum levels of YKL-40 increases in patients with acute myocardial infarction [J].Coron Artery Dis,2008 ;19(14) :257-63.
4Harutyunyan M, Gctze JP, Winkel P, et al. Serum YKL-40 predicts long-term mortality in patients with sta- ble coronary disease: a prognostic study within the CLAR- ICOR trial. Immunobiology, 2013, 218: 945-51.
5Henningsen KM, Therkelsen SK, Johansen JS, et al. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace, 2009, 11: 1032-1036.
6Rathcke CN, Persson F, Tarnow L, et al. YKL-40, a marker of inflammation and endothelial dysfunction, is el- evated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care, 2009, 32: 323- 328.
7Harutyunyan M, Christiansen M, Johansen JS, et al. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart fail- ure. Immunobiology, 2012, 217: 652-656.
8Swenne CA. Beyond lipid lowering: pleiotropic effects of statins in heart failure. Neth Heart J, 2013, 21 : 406- 407.
9Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008. Int J Cancer,2010,127:2893-2917.
10Forsberg AM, Kjellstrm L, Agrus L, et al. Prevalence of colonic neoplasia and advanced lesions in the normal population:a prospective population- based colonoscopy study. Scandinavian Journal of Gastroenterology,2012, 47 : 184 -190.
